

**UNITED STATES BANKRUPTCY COURT
SOUTHERN DISTRICT OF NEW YORK**

In re:

PURDUE PHARMA L.P., *et al.*,

Debtors.¹

Chapter 11

Case No. 19-23649 (RDD)

(Jointly Administered)

**TENTH MONTHLY FEE STATEMENT OF FTI CONSULTING, INC. FOR
COMPENSATION FOR SERVICES RENDERED AND REIMBURSEMENT OF
EXPENSES INCURRED AS FINANCIAL ADVISOR TO THE AD HOC COMMITTEE
OF GOVERNMENTAL AND OTHER CONTINGENT LITIGATION CLAIMANTS FOR
THE PERIOD FROM JULY 1, 2020 THROUGH JULY 31, 2020**

Name of Applicant:	FTI Consulting, Inc.
Authorized to provide Professional Services to:	Ad Hoc Committee of Governmental and Other Contingent Litigation Claimants
Date of Order Approving Debtors' Payment of Fees and Expenses of Applicant:	December 2, 2019 [ECF No. 553]
Period for which compensation and reimbursement is sought:	July 1, 2020 through July 31, 2020
Monthly Fees Incurred:	\$446,975.50

1. The Debtors in these chapter 11 cases, along with the last four digits of each Debtor's registration number in the applicable jurisdiction, are as follows: Purdue Pharma L.P. (7484), Purdue Pharma Inc. (7486), Purdue Transdermal Technologies L.P. (1868), Purdue Pharma Manufacturing L.P. (3821), Purdue Pharmaceuticals L.P. (0034), Imbrium Therapeutics L.P. (8810), Adlon Therapeutics L.P. (6745), Greenfield BioVentures L.P. (6150), Seven Seas Hill Corp. (4591), Ophir Green Corp. (4594), Purdue Pharma of Puerto Rico (3925), Avrio Health L.P. (4140), Purdue Pharmaceutical Products L.P. (3902), Purdue Neuroscience Company (4712), Nayatt Cove Lifesciences Inc. (7805), Button Land L.P. (7502), Rhodes Associates L.P. (N/A), Paul Land Inc. (7425), Quidnick Land L.P. (7584), Rhodes Pharmaceuticals L.P. (6166), Rhodes Technologies (7143), UDF LP (0495), SVC Pharma LP (5717), and SVC Pharma Inc. (4014). The Debtors' corporate headquarters is located at One Stamford Forum, 201 Tresser Boulevard, Stamford, CT 06901.

Monthly Expenses Incurred: \$0.00

Total Fees and Expenses Due: \$446,975.50

This is a: X monthly _____ interim _____ final application

PRIOR APPLICATIONS:

Docket No./Filed	Compensation Period	Requested		Approved	
		Fees	Expenses	Fees	Expenses
Docket No. 635 Filed On 12/9/2019	9/19/2019 – 10/31/2019	\$778,791.50	\$680.61	\$771,291.50	\$680.61
Docket No. 741 Filed On 1/13/2020	11/1/2019 – 11/30/2019	\$827,575.00	\$899.41	\$820,075.00	\$899.41
Docket No. 852 Filed on 2/20/2020	12/1/2019 – 12/31/2019	\$802,036.50	\$2,284.19	\$794,536.50	\$2,284.19
Docket No. 916 Filed on 3/12/2020	1/1/2020 – 1/31/2020	\$774,662.00	\$11,530.84	\$767,162.00	\$11,530.84
Docket No. 1090 Filed on 4/27/2020	2/1/2020 – 2/29/2020	\$615,089.00	\$6,141.22	\$610,714.00	\$6,141.22
Docket No. 1171 Filed on 5/19/2020	3/1/2020 – 3/31/2020	\$561,863.50	\$67.08	\$557,488.50	\$67.08
Docket No. 1251 Filed on 6/10/2020	4/1/2020 – 4/30/2020	\$428,303.00	\$1,732.28	\$423,928.00	\$1,732.28
Docket No. 1379 Filed on 7/13/2020	5/1/2020 – 5/31/2020	\$303,367.00	\$4,325.26	\$298,992.00	\$4,325.26
Docket No. 1651 Filed on 9/2/2020	6/1/2020 – 6/30/2020	\$374,753.00	\$96.90	\$ -	\$ -

Note: The fee examiner's agreed upon reductions of \$30,000 and \$17,500 were allocated evenly across fees from the first and second interim period, respectively.

This statement (the “**Fee Statement**”) of FTI Consulting, Inc. (together with its wholly owned subsidiaries and independent contractors, “**FTI**”) as financial advisor to the Ad Hoc Committee of Governmental and Other Contingent Litigation Claimants of Purdue Pharma L.P., *et al.* (the “**Committee**”) is submitted in accordance with the *Order Establishing Procedures for Interim Compensation and Reimbursement of Expenses for Retained Professionals* [ECF No. 529] and the *Order Authorizing the Debtors to Assume the Reimbursement Agreement and Pay the Fees and Expenses of the Ad Hoc Committee’s Professionals* [ECF No. 553] entered on November 21, 2019 and December 2, 2019, respectively, (the “**Orders**”). In support of this Fee Statement, FTI respectfully states as follows.

1. The fees and expenses for the period from July 1, 2020 through and including July 31, 2020 (the “**Tenth Fee Period**”) amount to:

Professional Fees	\$446,975.50
Expenses	<u>0.00</u>
TOTAL	<u>\$446,975.50</u>

2. In accordance with the Orders, FTI has separately recorded its fees in connection with or relating to the allocation of value among the Debtors’ creditors (the “**Allocation Fees**”) and has not, to the best of its knowledge, included Allocation Fees in this Fee Statement. If no timely and proper objection is made by a party-in-interest within fourteen (14) days after service of this Fee Statement, the Debtors are authorized to pay 80% of professional fees and 100% of out-of-pocket expenses. These amounts are presented below.

Professional Fees at 80%	\$357,580.40
Expenses at 100%	<u>0.00</u>
TOTAL	<u>\$357,580.40</u>

3. The professionals providing services, hourly billing rates, the aggregate hours worked by each professional, and the aggregate hourly fees for each professional during the Tenth Fee Period are set forth on the schedule annexed hereto as **Exhibit “A.”**
4. A summary of aggregate hours worked and aggregate hourly fees for each task code during the Tenth Fee Period is set forth on the schedule annexed hereto as **Exhibit “B.”**
5. Detailed time entry by task code during the Tenth Fee Period is set forth on the schedule annexed hereto as **Exhibit “C.”**
6. FTI reserves the right to request, in subsequent fee statements and applications, reimbursement of any additional expenses incurred during the Tenth Fee Period, as such expenses may not have been captured to date in FTI’s billing system.

NOTICE AND OBJECTION PROCEDURES

7. Objections to this Fee Statement, if any, must be filed with the Court and served upon the Notice Parties so as to be received no later than October 9, 2020 (the “**Objection Deadline**”), setting forth the nature of the objection and the amount of fees or expenses at issue (an “**Objection**”).
8. If no objections to this Fee Statement are filed and served as set forth above, the Debtors shall promptly pay eighty percent (80%) of the fees and one hundred percent (100%) of the expenses identified herein.
9. If an objection to this Fee Statement is received on or before the Objection Deadline, the Debtors shall withhold payment of that portion of this Fee Statement to which the objection is directed and promptly pay the remainder of the fees and disbursements in the percentages set forth above. To the extent such an objection is not resolved, it shall be

preserved and scheduled for consideration at the next interim fee application hearing to be heard by the Court.

Dated: New York, New York
September 25, 2020

FTI CONSULTING, INC.
Financial Advisors to the Ad Hoc Committee of
Governmental and Other Contingent Litigation
Claimants of Purdue Pharma L.P.

By: /s/ Matthew Diaz
Matthew Diaz, Senior Managing Director
Three Times Square, 10th Floor
New York, New York 10036
Telephone: (212) 499-3611
Email: matt.diaz@fticonsulting.com

EXHIBIT A

**PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649
SUMMARY OF HOURS BY PROFESSIONAL
FOR THE PERIOD JULY 1, 2020 TO JULY 31, 2020**

Professional	Position	Specialty	Billing Rate¹	Total Hours	Total Fees
Diaz, Matthew	Senior Managing Director	Restructuring	\$ 1,085	107.4	\$ 116,529.00
Greenblatt, Matthew	Senior Managing Director	Forensics	985	9.6	9,456.00
Joffe, Steven	Senior Managing Director	Tax	1,125	2.8	3,150.00
Simms, Steven	Senior Managing Director	Restructuring	1,295	3.9	5,050.50
Kyviakidis, Peter	Managing Director	Forensics	765	11.2	8,568.00
Suric, Emil	Senior Director	Healthcare	820	2.7	2,214.00
Costaldo, Nicole	Senior Director	Forensics	700	22.1	15,470.00
Bromberg, Brian	Director	Restructuring	815	184.8	150,612.00
Kim, Ye Darm	Senior Consultant	Restructuring	560	198.1	110,936.00
Mazzari, Meredith	Senior Consultant	Forensics	530	24.6	13,038.00
Kurtz, Emma	Consultant	Restructuring	415	28.8	11,952.00
GRAND TOTAL				596.0	\$ 446,975.50

1. Reflects blended hourly rates. Billing rates of international professionals have been translated to USD using the relevant spot rate.

EXHIBIT B

PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649
SUMMARY OF HOURS BY TASK
FOR THE PERIOD JULY 1, 2020 TO JULY 31, 2020

Task Code	Task Description	Total Hours	Total Fees
1	Current Operating Results & Events	8.3	\$ 3,779.50
7	Analysis of Domestic Business Plan	81.7	62,090.00
10	Analysis of Tax Issues	3.6	3,937.00
16	Analysis, Negotiate and Form of POR & DS	267.6	208,668.00
18	Review of Historical Transactions	70.7	49,437.00
19	Case Management	5.3	4,575.50
21	General Meetings with Counsel and/or Ad Hoc Committee	8.0	6,202.00
22	Meetings with Other Parties	23.4	21,256.50
24	Preparation of Fee Application	21.1	11,816.00
28	Review of IAC Business Plan	106.3	75,214.00
GRAND TOTAL¹		596.0	\$ 446,975.50

1. Billing rates of international professionals have been translated to USD using the relevant spot rate.

EXHIBIT C
PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649
DETAIL OF TIME ENTRIES
FOR THE PERIOD JULY 1, 2020 TO JULY 31, 2020

Task Category	Date	Professional	Hours	Activity
1	7/6/2020	Kurtz, Emma	0.6	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	7/7/2020	Kurtz, Emma	0.3	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	7/8/2020	Kurtz, Emma	0.3	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	7/9/2020	Kurtz, Emma	0.6	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	7/10/2020	Kurtz, Emma	0.5	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	7/13/2020	Kurtz, Emma	0.4	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	7/14/2020	Kurtz, Emma	0.3	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	7/15/2020	Kurtz, Emma	0.2	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	7/16/2020	Kurtz, Emma	0.4	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	7/17/2020	Kurtz, Emma	0.3	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	7/20/2020	Kurtz, Emma	0.6	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	7/21/2020	Kurtz, Emma	0.4	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	7/22/2020	Kurtz, Emma	0.6	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	7/23/2020	Kurtz, Emma	0.4	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	7/24/2020	Kurtz, Emma	0.3	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	7/27/2020	Kurtz, Emma	0.4	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	7/28/2020	Kurtz, Emma	0.3	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	7/29/2020	Kurtz, Emma	0.3	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	7/30/2020	Kurtz, Emma	0.2	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	7/31/2020	Diaz, Matthew	0.5	Review new product opportunity disclosed by Debtors and related documents and materials.
1	7/31/2020	Kurtz, Emma	0.4	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1 Total			8.3	
7	7/1/2020	Kim, Ye Darm	0.5	Review business plan support files for historical sales and EBITDA figures.
7	7/1/2020	Kim, Ye Darm	0.7	Review counsel's update to the AHC re: 2004 motions.
7	7/1/2020	Kim, Ye Darm	0.6	Process revisions to presentation re: Tribal diligence update presentation.
7	7/2/2020	Bromberg, Brian	0.8	Review Debtors' delayed bankruptcy case scenario presentation.

EXHIBIT C
PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649
DETAIL OF TIME ENTRIES
FOR THE PERIOD JULY 1, 2020 TO JULY 31, 2020

Task Category	Date	Professional	Hours	Activity
7	7/2/2020	Kim, Ye Darm	0.9	Review Debtors' delayed bankruptcy scenario presentation.
7	7/2/2020	Suric, Emil	1.7	Conduct preliminary Rhodes generics due diligence modeling and analysis.
7	7/3/2020	Kim, Ye Darm	2.2	Prepare updates to illustrative distributable value presentation.
7	7/4/2020	Diaz, Matthew	1.5	Review the financial update presentation for the NCSG.
7	7/5/2020	Kim, Ye Darm	1.8	Prepare slides for diligence update presentation to the NCSG.
7	7/5/2020	Kim, Ye Darm	1.2	Process revisions to the Mediation group financial presentation.
7	7/5/2020	Kim, Ye Darm	1.3	Prepare updates to slides re: Mediation group financial presentation.
7	7/5/2020	Kim, Ye Darm	1.1	Process revisions to the diligence update presentation to the NCSG.
7	7/5/2020	Diaz, Matthew	2.6	Perform detailed review of the financial diligence update presentation to the NCSG.
7	7/6/2020	Bromberg, Brian	3.4	Continue to evaluate opioid only scenario operating model.
7	7/6/2020	Bromberg, Brian	1.9	Evaluate opioid only scenario operating model from the Debtors.
7	7/6/2020	Kim, Ye Darm	0.3	Process updates to Mediation group financial presentation and diligence update presentation per Counsel's comments.
7	7/6/2020	Kim, Ye Darm	0.7	Review documents for information on PHI market sizing assumptions.
7	7/6/2020	Kim, Ye Darm	1.8	Review Debtors' opioid only business model.
7	7/6/2020	Kim, Ye Darm	0.3	Review PHI price scenarios analysis.
7	7/6/2020	Kim, Ye Darm	0.7	Participate in meeting with HL and Counsel re: diligence update presentations.
7	7/6/2020	Kim, Ye Darm	0.9	Participate in internal discussion re: diligence update presentations.
7	7/6/2020	Kim, Ye Darm	1.1	Process revisions to the Mediation group financial presentation and the diligence update presentation to the NCSG.
7	7/6/2020	Suric, Emil	0.5	Participate in due diligence call with subcommittee re: generic sales forecasts.
7	7/7/2020	Bromberg, Brian	1.3	Review previous public health initiatives slides to create new presentation.
7	7/7/2020	Bromberg, Brian	0.5	Submit additional requests to Debtors on opioid only scenario assumptions.
7	7/7/2020	Diaz, Matthew	0.8	Review latest information re: the PHI initiatives for diligence update.
7	7/7/2020	Diaz, Matthew	0.5	Participate in a call with the Debtors to discuss the domestic business plan.
7	7/7/2020	Diaz, Matthew	1.3	Review the opioid only forecast and related due diligence questions.
7	7/7/2020	Diaz, Matthew	2.2	Review the sensitized business plan and related assumptions.
7	7/7/2020	Kim, Ye Darm	1.3	Prepare one-pager re: PHI diligence for D&P.
7	7/7/2020	Kim, Ye Darm	0.9	Review PHI analyses to prepare summary sheet to share with D&P.
7	7/7/2020	Kim, Ye Darm	0.6	Review historical audited financial statements for margin assumptions.
7	7/8/2020	Bromberg, Brian	1.3	Review Debtors' continued operations scenario and related assumptions.
7	7/8/2020	Bromberg, Brian	1.0	Participate in call with Debtors regarding delayed bankruptcy costs.
7	7/8/2020	Bromberg, Brian	0.7	Review and provide revisions re: public health initiatives diligence update presentation.
7	7/8/2020	Bromberg, Brian	0.9	Review prior OxyContin forecast model for previous sales assumptions.
7	7/8/2020	Bromberg, Brian	0.4	Prepare template for data request of Debtors re: domestic business plan diligence.
7	7/8/2020	Bromberg, Brian	0.7	Finalize template for data request re: domestic business plan diligence.

EXHIBIT C
PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649
DETAIL OF TIME ENTRIES
FOR THE PERIOD JULY 1, 2020 TO JULY 31, 2020

Task Category	Date	Professional	Hours	Activity
7	7/8/2020	Diaz, Matthew	0.6	Prepare for the call with the Debtors re the OxyContin forecasts in the domestic business plan.
7	7/8/2020	Diaz, Matthew	1.0	Participate in call with the Debtors and advisors to discuss OxyContin forecast assumptions.
7	7/8/2020	Kim, Ye Darm	0.7	Process revisions to PHI one-pager for D&P.
7	7/8/2020	Kim, Ye Darm	1.2	Review Debtor-provided files re: historical OxyContin margins.
7	7/8/2020	Kim, Ye Darm	1.3	Review business forecast cash assumptions and prior materials provided by Debtors.
7	7/8/2020	Bromberg, Brian	2.1	Review end of year cash projection per Debtors' business plan.
7	7/8/2020	Suric, Emil	0.5	Participate in internal discussion on next steps on Debtors' forecast diligence process.
7	7/9/2020	Diaz, Matthew	1.3	Review the updated domestic business plan cash flow forecasts.
7	7/9/2020	Bromberg, Brian	1.3	Review updated Debtors business plan model and scenarios.
7	7/9/2020	Bromberg, Brian	0.3	Discuss latest updates re: public health initiatives on call with team.
7	7/10/2020	Bromberg, Brian	0.5	Discuss public health initiatives updates with Debtor advisors.
7	7/10/2020	Bromberg, Brian	1.3	Process updates to presentation on public health initiatives.
7	7/10/2020	Bromberg, Brian	0.5	Discuss public health initiatives presentation with internal team.
7	7/10/2020	Bromberg, Brian	0.5	Review public health initiatives diligence update deck.
7	7/10/2020	Diaz, Matthew	1.2	Review the PHI diligence update presentation.
7	7/10/2020	Kim, Ye Darm	0.5	Participate in discussion re: PHI diligence update.
7	7/10/2020	Kim, Ye Darm	0.7	Process updates to draft PHI diligence update deck.
7	7/14/2020	Bromberg, Brian	0.8	Participate in call with Debtors on new domestic business scenarios.
7	7/14/2020	Bromberg, Brian	0.9	Review the updated public health initiatives diligence update deck.
7	7/14/2020	Diaz, Matthew	0.7	Review the updated PHI diligence slides.
7	7/14/2020	Kim, Ye Darm	1.4	Process revisions to PHI overview presentation for the DOJ.
7	7/14/2020	Kim, Ye Darm	1.6	Process revisions to presentation on PHI initiatives for DOJ.
7	7/15/2020	Bromberg, Brian	1.2	Review public health initiatives deck for PEO information.
7	7/15/2020	Kim, Ye Darm	0.4	Continue review of source materials for the PHI presentation re: PEO documents.
7	7/15/2020	Kim, Ye Darm	0.6	Review source documents for PHI presentation re: PEO.
7	7/15/2020	Kim, Ye Darm	1.9	Process revisions to PHI presentation to the DOJ.
7	7/21/2020	Kim, Ye Darm	1.3	Review business plan related documents on the dataroom for potential adjustments to distributable value presentation.
7	7/21/2020	Kim, Ye Darm	0.4	Source PEO information relied upon for the PHI presentation to the DOJ.
7	7/22/2020	Diaz, Matthew	1.2	Review the PHI diligence update presentation.
7	7/22/2020	Kim, Ye Darm	0.4	Process revisions to the PHI presentation to the DOJ.
7	7/27/2020	Bromberg, Brian	0.6	Prepare responses to questions re: public health initiatives updates.
7	7/27/2020	Kim, Ye Darm	0.7	Review YTD Nalmefene costs document from the Debtors.
7	7/27/2020	Kim, Ye Darm	1.4	Review new documents in dataroom to identify documents responsive to diligence requests.
7	7/29/2020	Bromberg, Brian	1.3	Review new product opportunity-related materials uploaded by the Debtors.
7	7/29/2020	Kim, Ye Darm	0.8	Review new product opportunity-related materials uploaded by the Debtors.
7	7/30/2020	Bromberg, Brian	0.4	Prepare for call with Debtors re: new product opportunity.
7	7/30/2020	Bromberg, Brian	0.4	Participate in call with Debtors re: new product opportunity.
7	7/30/2020	Bromberg, Brian	0.6	Coordinate with AHC advisors re: new product opportunity.
7	7/30/2020	Diaz, Matthew	0.7	Review the updated business plan sensitivity scenarios.

EXHIBIT C
PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649
DETAIL OF TIME ENTRIES
FOR THE PERIOD JULY 1, 2020 TO JULY 31, 2020

Task Category	Date	Professional	Hours	Activity
7	7/31/2020	Bromberg, Brian	0.5	Review the Debtors' public health initiative budget.
7	7/31/2020	Bromberg, Brian	3.1	Review new OxyContin projections from the Debtors.
7 Total			81.7	
10	7/2/2020	Joffe, Steven	0.5	Review of PJT deck on go-forward scenarios for potential tax impacts.
10	7/9/2020	Joffe, Steven	0.6	Participate in call with DPW, KL, BR re: PBC structure.
10	7/10/2020	Joffe, Steven	0.3	Review of internal summary of DPW call re: potential tax issues.
10	7/15/2020	Bromberg, Brian	0.3	Review CARES act tax refund impact on Purdue.
10	7/15/2020	Diaz, Matthew	0.5	Review of the CARES legislation impact on tax refunds.
10	7/22/2020	Joffe, Steven	1.4	Participate on AHC call re: values of different go-forward scenarios.
10 Total			3.6	
16	7/1/2020	Bromberg, Brian	0.6	Review distributable value presentation for call with tribes.
16	7/3/2020	Diaz, Matthew	1.8	Review the updated waterfall/distributable value analysis.
16	7/6/2020	Bromberg, Brian	3.7	Create new distributable value scenario from opioid only model.
16	7/6/2020	Bromberg, Brian	1.7	Participate in call with UCC and NCSG on distributable value.
16	7/6/2020	Bromberg, Brian	0.5	Review distributable value presentation for PEO issues.
16	7/6/2020	Bromberg, Brian	0.8	Update distributable value presentation based on comments.
16	7/6/2020	Bromberg, Brian	0.7	Discuss distributable value presentation with counsel.
16	7/6/2020	Bromberg, Brian	1.5	Participate in call with NCSG on distributable value.
16	7/6/2020	Diaz, Matthew	2.4	Review the recovery sensitivity scenarios re: waterfall/distributable value .
16	7/6/2020	Diaz, Matthew	2.1	Review of the updated distributable value/waterfall analysis.
16	7/6/2020	Kim, Ye Darm	1.9	Prepare analysis of potential fee expense to estate for professional fee burn analysis.
16	7/7/2020	Kim, Ye Darm	0.8	Process additional updates re: distributable value analysis.
16	7/7/2020	Kim, Ye Darm	1.6	Update presentation slides re: distributable value analysis.
16	7/7/2020	Kim, Ye Darm	1.1	Process revisions to distributable value presentation re: LOE 2027 scenario.
16	7/7/2020	Kim, Ye Darm	0.6	Participate in call re: distributable value analysis scenarios.
16	7/7/2020	Kim, Ye Darm	1.8	Prepare model for distributable value analysis presentation.
16	7/7/2020	Kim, Ye Darm	0.9	Review financial information for updated distributable value analysis.
16	7/7/2020	Kim, Ye Darm	0.5	Participate in discussion re: distributable value analysis presentation.
16	7/7/2020	Bromberg, Brian	1.5	Discuss new distributable value presentation with team.
16	7/7/2020	Bromberg, Brian	1.7	Review revisions to opioid only scenario.
16	7/7/2020	Bromberg, Brian	2.8	Create slides for new scenario on distributable value.
16	7/7/2020	Bromberg, Brian	3.0	Finalize draft of revised distributable value presentation.
16	7/7/2020	Kim, Ye Darm	1.1	Update professional fee burn analysis per Counsel's revisions.
16	7/8/2020	Kim, Ye Darm	1.1	Update distributable value analysis presentation for OyxContin sales scenarios.
16	7/8/2020	Kim, Ye Darm	0.4	Process revisions to distributable value analysis presentation.
16	7/8/2020	Kim, Ye Darm	2.3	Update distributable value analysis re: OxyContin sale scenarios.
16	7/8/2020	Kim, Ye Darm	1.0	Participate in call with PJT re: delayed bankruptcy scenario.
16	7/8/2020	Kim, Ye Darm	0.9	Review OxyContin sale scenarios for distributable value analysis.
16	7/8/2020	Diaz, Matthew	0.8	Participate on a call with the UCC to discuss the waterfall/distributable value analysis.
16	7/8/2020	Diaz, Matthew	1.3	Review the updated waterfall/distributable value analysis.
16	7/8/2020	Kim, Ye Darm	0.5	Process revisions to professional fee burn rate analysis.
16	7/9/2020	Bromberg, Brian	1.4	Prepare summary of cash projection findings for distributable value.
16	7/9/2020	Bromberg, Brian	0.8	Prepare for call on Debtors' cash projections for distributable value.

EXHIBIT C
PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649
DETAIL OF TIME ENTRIES
FOR THE PERIOD JULY 1, 2020 TO JULY 31, 2020

Task Category	Date	Professional	Hours	Activity
16	7/9/2020	Bromberg, Brian	0.5	Discuss Debtors' cash projections for distributable value with internal team.
16	7/9/2020	Bromberg, Brian	0.5	Prepare for internal team discussion on cash projections for distributable value.
16	7/9/2020	Bromberg, Brian	0.9	Participate in discussion re: cash projections with Debtor advisors for distributable value.
16	7/9/2020	Kim, Ye Darm	0.6	Participate in discussion with Debtors re: PPLP forecast assumptions.
16	7/9/2020	Kim, Ye Darm	2.3	Update model for additional cash flow assumptions re: distributable value analysis.
16	7/9/2020	Kim, Ye Darm	0.9	Review call notes re: cash call with Alix/PJT for distributable value.
16	7/9/2020	Kim, Ye Darm	1.9	Update model for operating cash flows and PBC scenario re: distributable value analysis.
16	7/9/2020	Kim, Ye Darm	0.8	Process revisions to presentation to injury claimants re: distributable value.
16	7/9/2020	Kim, Ye Darm	0.5	Participate in cash forecasts re: distributable value analysis.
16	7/9/2020	Bromberg, Brian	0.5	Participate in call with personal injury claimants on distributable value.
16	7/9/2020	Bromberg, Brian	2.8	Work on additional scenarios for the distributable value analysis.
16	7/9/2020	Diaz, Matthew	1.5	Review the updated waterfall/distributable value and related sensitivities.
16	7/9/2020	Simms, Steven	0.3	Review latest draft of distributable value recovery presentation.
16	7/9/2020	Simms, Steven	0.9	Participate on call with claimants re: distributable value recovery analysis.
16	7/10/2020	Bromberg, Brian	0.4	Discuss Debtors' cash projection with internal team re: distributable value.
16	7/10/2020	Kim, Ye Darm	1.8	Process revisions to the presentation for new base case assumptions re: distributable value analysis.
16	7/10/2020	Kim, Ye Darm	2.6	Process revisions to distributable value analysis model for restricted cash.
16	7/10/2020	Kim, Ye Darm	1.3	Process updates to model for distributable value analysis for PBC case.
16	7/10/2020	Kim, Ye Darm	2.4	Process revisions to the presentation re: Distributable Value Analysis.
16	7/10/2020	Bromberg, Brian	3.2	Edit presentation and excel model on distributable value.
16	7/10/2020	Bromberg, Brian	1.2	Review and comment on distributable value presentation.
16	7/10/2020	Bromberg, Brian	1.7	Review latest distributable value presentation and comment on new scenarios.
16	7/10/2020	Diaz, Matthew	2.1	Review the updated waterfall/distributable value analysis.
16	7/12/2020	Kim, Ye Darm	1.0	Participate on call re: distributable value presentation updates.
16	7/12/2020	Kim, Ye Darm	2.3	Process revisions to the presentation re: distributable value analysis.
16	7/12/2020	Kim, Ye Darm	1.9	Process revisions to the presentation re: distributable value analysis.
16	7/12/2020	Bromberg, Brian	0.8	Discuss distributable value presentation with team.
16	7/12/2020	Bromberg, Brian	3.0	Review and comment on distributable value presentation.
16	7/12/2020	Diaz, Matthew	2.5	Review the updated waterfall/distributable value recovery analysis for the committee.
16	7/13/2020	Bromberg, Brian	1.7	Review Debtor-provided opioid only business model.
16	7/13/2020	Kim, Ye Darm	0.6	Participate in internal meeting re: revisions to distributable value presentation.
16	7/13/2020	Kim, Ye Darm	2.2	Process revisions to distributable value analysis presentation.
16	7/13/2020	Kim, Ye Darm	1.1	Participate in internal discussion re: revisions to distributable value presentation.

EXHIBIT C
PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649
DETAIL OF TIME ENTRIES
FOR THE PERIOD JULY 1, 2020 TO JULY 31, 2020

Task Category	Date	Professional	Hours	Activity
16	7/13/2020	Kim, Ye Darm	1.2	Update model for new assumptions re: distributable value analysis.
16	7/13/2020	Bromberg, Brian	1.6	Discuss latest distributable presentation with internal team.
16	7/13/2020	Bromberg, Brian	0.7	Discuss distributable presentation with internal team.
16	7/13/2020	Bromberg, Brian	1.2	Discuss distributable value scenarios with UCC after discussion with Debtors.
16	7/13/2020	Bromberg, Brian	1.1	Discuss distributable value scenarios with UCC.
16	7/13/2020	Bromberg, Brian	3.5	Revise and review distributable value scenarios.
16	7/13/2020	Bromberg, Brian	1.1	Discuss OxyContin only scenario with Debtors.
16	7/13/2020	Bromberg, Brian	2.3	Review latest distributable value presentation and comment on new scenarios.
16	7/13/2020	Diaz, Matthew	1.0	Participate in a call with Province and HL to discuss the waterfall/distributable value analysis.
16	7/13/2020	Diaz, Matthew	0.9	Participate in a follow up call with HL and Province to discuss the waterfall/distributable value analysis.
16	7/13/2020	Diaz, Matthew	2.6	Review the slides to the UCC and the Company on the waterfall/distributable value analysis.
16	7/13/2020	Diaz, Matthew	1.0	Participate on a call with the Debtors to discuss the waterfall/distributable value analysis.
16	7/13/2020	Diaz, Matthew	3.5	Review the updated waterfall/distributable value analysis.
16	7/13/2020	Kim, Ye Darm	1.0	Participate in call with Debtors' advisors re: opioid only oxy-only scenario for distributable value analysis.
16	7/13/2020	Kim, Ye Darm	0.6	Participate in call with PJT re: joint presentation on distributable value.
16	7/14/2020	Kim, Ye Darm	2.7	Review and process revisions from the UCC professionals re: distributable value presentation.
16	7/14/2020	Kim, Ye Darm	1.2	Process additional comments and revisions from the UCC professionals re: distributable value presentation.
16	7/14/2020	Bromberg, Brian	1.7	Review latest distributable value presentation and comment.
16	7/14/2020	Bromberg, Brian	1.8	Prepare comments for the updated distributable value deck.
16	7/14/2020	Diaz, Matthew	0.3	Participate in a call with the case financial advisors to discuss the waterfall/distributable value analysis.
16	7/14/2020	Diaz, Matthew	1.6	Review of the updated waterfall/distributable value presentation.
16	7/14/2020	Kim, Ye Darm	0.3	Participate in call with PJT re: joint presentation on distributable value.
16	7/15/2020	Bromberg, Brian	3.2	Review newly provided models for scenarios re: PBC case, opioid-only.
16	7/15/2020	Diaz, Matthew	1.2	Review the new opioid only business plan model from the Debtors.
16	7/15/2020	Kim, Ye Darm	0.8	Update figures in model for latest distributable value assumptions.
16	7/15/2020	Kim, Ye Darm	2.3	Process revisions to presentation on distributable value analysis for new model assumptions.
16	7/15/2020	Kim, Ye Darm	3.4	Process updates to distributable value model for new assumptions.
16	7/15/2020	Kim, Ye Darm	1.4	Process revisions to presentation on distributable value per internal comments.
16	7/15/2020	Kim, Ye Darm	1.3	Process updates to distributable value analysis model for new assumptions.
16	7/15/2020	Kim, Ye Darm	0.5	Participate in internal call re: updates to distributable value presentation.
16	7/15/2020	Kim, Ye Darm	1.6	Continue processing updates to distributable value analysis model for new assumptions.

EXHIBIT C
PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649
DETAIL OF TIME ENTRIES
FOR THE PERIOD JULY 1, 2020 TO JULY 31, 2020

Task Category	Date	Professional	Hours	Activity
16	7/15/2020	Kim, Ye Darm	1.5	Process revisions to presentation on distributable value for new model assumptions.
16	7/15/2020	Kim, Ye Darm	0.6	Prepare diligence questions re: distributable value assumptions.
16	7/15/2020	Kim, Ye Darm	0.6	Participate in internal call re: call with Debtors' on distributable value analysis.
16	7/15/2020	Kim, Ye Darm	0.5	Participate in internal call re: updates to distributable value presentation.
16	7/15/2020	Bromberg, Brian	2.5	Review and comment on new version of distributable value presentation.
16	7/15/2020	Bromberg, Brian	1.3	Discuss distributable value analysis with internal team.
16	7/15/2020	Bromberg, Brian	2.0	Review and comment on distributable value presentation.
16	7/15/2020	Bromberg, Brian	1.3	Participate in call with Debtors on new operating scenarios.
16	7/15/2020	Bromberg, Brian	1.3	Discuss changes to distributable value presentation after Debtor call with team.
16	7/15/2020	Bromberg, Brian	0.5	Review updated distributable value deck.
16	7/15/2020	Bromberg, Brian	0.6	Review Debtors' notes on latest operating scenarios.
16	7/15/2020	Bromberg, Brian	0.9	Review internal comments received on distributable value presentation.
16	7/15/2020	Diaz, Matthew	2.5	Review the updated waterfall/distributable value analysis scenarios from the Debtors.
16	7/15/2020	Diaz, Matthew	3.4	Review the updated waterfall/distributable value analysis materials and related changes.
16	7/15/2020	Diaz, Matthew	1.5	Participate in a call with the Debtors and other key stakeholder advisors to discuss various waterfall/distributable value recovery scenarios.
16	7/15/2020	Kim, Ye Darm	1.6	Participate in call with PJT and Debtors re: distributable value analysis assumptions.
16	7/16/2020	Bromberg, Brian	1.2	Create question and diligence list for Debtors re: new scenarios.
16	7/16/2020	Kim, Ye Darm	0.7	Participate in internal discussion re: joint presentation on distributable value.
16	7/16/2020	Kim, Ye Darm	2.1	Process revisions to model and presentation re: distributable value analyses.
16	7/16/2020	Kim, Ye Darm	1.7	Process revisions to presentation on distributable value per comments from Debtors and UCC advisors.
16	7/16/2020	Kim, Ye Darm	2.3	Process updates to joint presentation on distributable value per comments from UCC advisors.
16	7/16/2020	Kim, Ye Darm	1.0	Participate in preparation meeting for call with Debtors re: joint presentation.
16	7/16/2020	Bromberg, Brian	0.8	Respond to UCC comments on distributable value presentation.
16	7/16/2020	Bromberg, Brian	1.0	Discuss additional diligence questions and distributable value presentation with team.
16	7/16/2020	Bromberg, Brian	2.1	Review and comment on updated distributable value presentation.
16	7/16/2020	Bromberg, Brian	1.0	Discuss latest distributable presentation with internal team.
16	7/16/2020	Bromberg, Brian	0.8	Review updated distributable value deck and prepare comments.
16	7/16/2020	Bromberg, Brian	1.0	Discuss distributable value scenario diligence questions with Debtor advisors.
16	7/16/2020	Bromberg, Brian	1.0	Catch up with team on latest diligence responses from Debtors re: operating scenarios.

EXHIBIT C
PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649
DETAIL OF TIME ENTRIES
FOR THE PERIOD JULY 1, 2020 TO JULY 31, 2020

Task Category	Date	Professional	Hours	Activity
16	7/16/2020	Diaz, Matthew	3.4	Perform detailed review of the updated presentation materials incorporating the new scenarios from the Debtors.
16	7/16/2020	Diaz, Matthew	0.5	Participate in a call with Province and Houlihan to discuss the updated scenarios.
16	7/16/2020	Diaz, Matthew	1.0	Call with the Debtors to discuss our questions on the waterfall/distributable value sensitivities.
16	7/16/2020	Diaz, Matthew	2.6	Review the new waterfall/distributable value scenarios and sensitivities from the Debtors.
16	7/16/2020	Kim, Ye Darm	1.0	Participate in call with Debtors and PJT re: distributable value analysis presentation.
16	7/17/2020	Kim, Ye Darm	0.6	Review comments and revisions from UCC advisors re: distributable value model.
16	7/17/2020	Kim, Ye Darm	2.9	Process revisions to distributable value analysis model and presentation for new assumptions.
16	7/17/2020	Kim, Ye Darm	2.3	Process updates to distributable value analysis model and presentation for new assumptions.
16	7/17/2020	Kim, Ye Darm	1.4	Process updates to distributable value presentation for internal comments and UCC advisor revisions.
16	7/17/2020	Bromberg, Brian	1.3	Review updated version of distributable value presentation and share with Debtors.
16	7/17/2020	Bromberg, Brian	0.5	Discuss UCC comments on distributable value presentation with team.
16	7/17/2020	Bromberg, Brian	1.3	Prepare comments on latest distributable value presentation.
16	7/17/2020	Diaz, Matthew	0.9	Review comments from the UCC on the waterfall/distributable value presentation.
16	7/17/2020	Diaz, Matthew	1.2	Review the updated waterfall/distributable value presentation to send to the Debtors.
16	7/18/2020	Kim, Ye Darm	2.1	Process revisions to the distributable value analysis and presentation per comments from the Debtors' advisors.
16	7/18/2020	Kim, Ye Darm	2.3	Process revisions to the distributable value presentation per comments from UCC advisors.
16	7/18/2020	Bromberg, Brian	3.1	Prepare comments on latest distributable value presentation based on Debtor and UCC comments.
16	7/18/2020	Diaz, Matthew	1.9	Review diligence questions and related due diligence on the waterfall/distributable value analysis.
16	7/19/2020	Kim, Ye Darm	2.7	Process updates to model re: distributable value analysis.
16	7/19/2020	Kim, Ye Darm	2.3	Process revisions to the distributable value analysis per the Debtors comments.
16	7/19/2020	Kim, Ye Darm	0.6	Prepare analysis in response to Debtors' questions about distributable value assumptions.
16	7/19/2020	Bromberg, Brian	2.2	Review updated distributable value presentation and illustrative bridge per Debtor and UCC comments.
16	7/19/2020	Diaz, Matthew	2.4	Review the updated waterfall/distributable value analysis.
16	7/20/2020	Kim, Ye Darm	0.4	Prepare responses to PJT's questions re: distributable value assumptions.
16	7/20/2020	Kim, Ye Darm	2.1	Process revisions to distributable value presentation for new assumptions from the Debtors' advisors.
16	7/20/2020	Kim, Ye Darm	0.9	Process revisions to the distributable value model for new assumptions.

EXHIBIT C
PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649
DETAIL OF TIME ENTRIES
FOR THE PERIOD JULY 1, 2020 TO JULY 31, 2020

Task Category	Date	Professional	Hours	Activity
16	7/20/2020	Bromberg, Brian	0.9	Review edits to updated distributable value analysis.
16	7/20/2020	Bromberg, Brian	0.9	Review Debtors' comments re: distributable value analysis.
16	7/20/2020	Diaz, Matthew	1.7	Review the updated waterfall/distributable value analysis.
16	7/21/2020	Kim, Ye Darm	0.8	Process revisions to the distributable value joint presentation for internal comments.
16	7/21/2020	Kim, Ye Darm	1.8	Process revisions to distributable value analysis model for new assumptions.
16	7/21/2020	Kim, Ye Darm	0.8	Process revisions to joint presentation on distributable value for internal comments.
16	7/21/2020	Kim, Ye Darm	0.7	Process revisions to the distributable value presentation per internal comments.
16	7/21/2020	Kim, Ye Darm	0.5	Participate in call re: coordination on distributable value joint presentation.
16	7/21/2020	Kim, Ye Darm	0.5	Process revisions to distributable value presentation per Debtors' comments.
16	7/21/2020	Kim, Ye Darm	0.5	Participate in internal meeting re: distributable value presentation.
16	7/21/2020	Kim, Ye Darm	2.5	Process revisions to the distributable value analysis model for adjustment to assumptions from the Debtors.
16	7/21/2020	Kim, Ye Darm	1.1	Perform detailed QC of distributable value joint presentation.
16	7/21/2020	Kim, Ye Darm	1.2	Process additional updates to the distributable value model per assumptions from the Debtors.
16	7/21/2020	Bromberg, Brian	1.3	Finalize distributable value presentation and share with Counsel.
16	7/21/2020	Bromberg, Brian	1.3	Review additional changes based on UCC comments on to distributable value presentation.
16	7/21/2020	Bromberg, Brian	2.5	Process revisions to distributable value presentation.
16	7/21/2020	Bromberg, Brian	0.5	Review latest draft of distributable value analysis ahead of discussion with team.
16	7/21/2020	Bromberg, Brian	0.5	Discuss distributable value analysis with internal team.
16	7/21/2020	Bromberg, Brian	1.5	Review edits to updated distributable value presentation.
16	7/21/2020	Bromberg, Brian	1.0	Review new scenario changes to distributable value presentation.
16	7/21/2020	Bromberg, Brian	0.8	Discuss distributable value presentation with UCC.
16	7/21/2020	Diaz, Matthew	3.1	Perform detailed review of the updated waterfall/distributable value analysis.
16	7/21/2020	Diaz, Matthew	2.5	Review the updated changes to the waterfall/distributable value scenarios in the joint presentation.
16	7/21/2020	Diaz, Matthew	0.5	Participate in call with the Debtors to discuss the joint presentation meeting.
16	7/21/2020	Diaz, Matthew	0.6	Participate in a call with the case financial advisors to prepare for the joint presentation meeting.
16	7/21/2020	Diaz, Matthew	3.5	Perform detailed review of the slides for the joint waterfall/distributable value recovery presentation.
16	7/22/2020	Diaz, Matthew	0.9	Review the Debtors' updated opioid-only scenario assumptions and model.
16	7/22/2020	Bromberg, Brian	0.8	Revise distributable value presentation for upcoming meeting.
16	7/22/2020	Diaz, Matthew	0.6	Review follow ups and additional workstreams coming out of the joint presentation call.
16	7/22/2020	Kim, Ye Darm	1.8	Participate in call re: joint financial presentation on distributable value.
16	7/29/2020	Diaz, Matthew	1.2	Review the updated distributable value/waterfall analysis.
16	7/31/2020	Bromberg, Brian	2.7	Review updates to distributable value analysis and value breakdown.

EXHIBIT C
PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649
DETAIL OF TIME ENTRIES
FOR THE PERIOD JULY 1, 2020 TO JULY 31, 2020

Task Category	Date	Professional	Hours	Activity
16 Total			267.6	
18	7/2/2020	Bromberg, Brian	0.8	Discuss historical cash transfer report with internal team.
18	7/2/2020	Costaldo, Nicole	1.2	Attend internal discussion with team to discuss Alix Partner's analyses re: 1B report.
18	7/2/2020	Diaz, Matthew	1.1	Perform review of AlixPartner's 1B report.
18	7/2/2020	Greenblatt, Matthew	1.2	Attend internal discussion with team to discuss Alix Partner's analyses re: 1B report.
18	7/2/2020	Mazzari, Meredith	0.3	Participate in post-call discussion re: Transfers of Value reports.
18	7/6/2020	Costaldo, Nicole	3.2	Review and analyze the AlixPartners Intercompany and Non-Cash Transfers report to identify transfers that require further testing re: Arms Length negotiations.
18	7/6/2020	Costaldo, Nicole	1.2	Continue analysis of the AlixPartners Intercompany and Non-Cash Transfers report to identify transfers that require further testing re: Arms Length negotiations.
18	7/6/2020	Costaldo, Nicole	2.7	Attend meeting and discuss with forensic accountants re: workplan for analysis of arms length negotiations of transfers.
18	7/6/2020	Kyviakidis, Peter	1.0	Prepare for call re: selection of transfers for potential further investigatory inquiry re: arms length negotiations.
18	7/6/2020	Kyviakidis, Peter	2.5	Analyze Intercompany and Non-Cash Transfers of Value Analysis re: identification of potential further investigatory inquiry.
18	7/6/2020	Kyviakidis, Peter	1.3	Participate in call re: selection of tranfers for potential further investigatory inquiry re: arms length negotiations.
18	7/6/2020	Mazzari, Meredith	1.2	Participate in call re: selection of tranfers for potential further investigatory inquiry re: arms length negotiations.
18	7/6/2020	Mazzari, Meredith	0.4	Continue to review audited financial statements for notes/references to non-cash transfers
18	7/6/2020	Mazzari, Meredith	1.0	Prepare for internal call re: 1B Report additional inquiries.
18	7/6/2020	Mazzari, Meredith	3.0	Review audited financial statements for notes/references to non-cash transfers.
18	7/7/2020	Costaldo, Nicole	3.1	Participate in meeting re: transfers requiring further testing and next steps to explain and identify 3rd party support or disclosures in the audited financial statements.
18	7/7/2020	Greenblatt, Matthew	0.8	Continue review of AlixPartners' Non-Cash Transfers report and discuss with team to develop investigative workplan.
18	7/7/2020	Kyviakidis, Peter	0.8	Participate on internal call re: selection of certain intercompany transactions and non-cash transfers of value between the Debtor Entities and related IACs for potential further investigatory testing.
18	7/7/2020	Mazzari, Meredith	0.5	Quality check and review slide deck summarizing proposed selection of transfers for testing.
18	7/7/2020	Mazzari, Meredith	0.5	Participate on internal status update call re: transfers of value reports.
18	7/8/2020	Bromberg, Brian	0.4	Review discovery files produced by Milbank.
18	7/8/2020	Costaldo, Nicole	1.0	Participate in discussion re: updates to transfers requiring further testing.
18	7/8/2020	Kyviakidis, Peter	1.0	Participate in discussion re: updates to transfers requiring further testing.
18	7/8/2020	Mazzari, Meredith	0.9	Participate in discussion re: updates to transfers requiring further testing.
18	7/8/2020	Mazzari, Meredith	2.5	Review selected transfers and determine whether they are disclosed in the audit financial statements.

EXHIBIT C
PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649
DETAIL OF TIME ENTRIES
FOR THE PERIOD JULY 1, 2020 TO JULY 31, 2020

Task Category	Date	Professional	Hours	Activity
18	7/8/2020	Mazzari, Meredith	0.5	Quality check and review latest slide deck summarizing proposed selection of transfers for testing.
18	7/9/2020	Costaldo, Nicole	1.3	Participate on call with team re: transfers that require further testing.
18	7/9/2020	Costaldo, Nicole	2.5	Revise presentation of selected transfers by type of transfer (e.g. from Purdue to IAC) and by additional recoupable value.
18	7/9/2020	Kyviakidis, Peter	1.3	Participate on call with team re: transfers that require further testing.
18	7/9/2020	Mazzari, Meredith	0.7	Review selected transfers and determine whether they are disclosed in the audit financial statements.
18	7/9/2020	Mazzari, Meredith	0.5	Prepare spreadsheet compiled of names comprised of bankruptcy estate to compare against those entities included within audited financial statements.
18	7/9/2020	Mazzari, Meredith	1.2	Participate on call with team re: transfers that require further testing.
18	7/10/2020	Costaldo, Nicole	2.5	Finalize draft presentation of select Intercompany and Non-Cash transfers identified that require further testing.
18	7/10/2020	Greenblatt, Matthew	1.2	Participate in discussions with team re: continued development of proposed workplan for testing of AlixPartners' Non-Cash Transfers report.
18	7/10/2020	Kyviakidis, Peter	0.5	Participate on a call to discuss workplan re: diligence of the selection of certain transfers of value between the Debtor Entities and related IACs.
18	7/10/2020	Kyviakidis, Peter	1.0	Participate on a call with larger internal team in order to discuss the selection of certain intercompany and non-cash transfers of value between the Debtor Entities and related IACs for potential further investigatory inquiry.
18	7/10/2020	Mazzari, Meredith	1.1	Review selected transfers to determine whether non-debtor entities/counterparties are included in audited financial statements.
18	7/10/2020	Mazzari, Meredith	0.3	Review selected transfers and determine whether they are disclosed in the audit financial statements.
18	7/10/2020	Mazzari, Meredith	1.1	Participate on a call with larger internal team in order to discuss the selection of certain intercompany and non-cash transfers of value between the Debtor Entities and related IACs for potential further investigatory inquiry.
18	7/10/2020	Mazzari, Meredith	0.4	Participate on a call to discuss workplan re: diligence of the selection of certain transfers of value between the Debtor Entities and related IACs.
18	7/10/2020	Mazzari, Meredith	0.1	Update spreadsheet compiled of names comprised of bankruptcy estate to compare against those entities included within audited financial statements.
18	7/13/2020	Greenblatt, Matthew	0.8	Continued reviewing the AlixPartners' Non-Cash Transfers report and initial testing procedures.
18	7/13/2020	Kyviakidis, Peter	0.5	Participate on a call to discuss the draft presentation re: diligence of the selection of certain transfers of value between the Debtor Entities and related IACs.
18	7/13/2020	Mazzari, Meredith	0.3	Participate on a call to discuss the draft presentation re: diligence of the selection of certain transfers of value between the Debtor Entities and related IACs.
18	7/13/2020	Mazzari, Meredith	0.3	Review selected transfers to determine whether non-debtor entities/counterparties are included in audited financial statements.

EXHIBIT C
PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649
DETAIL OF TIME ENTRIES
FOR THE PERIOD JULY 1, 2020 TO JULY 31, 2020

Task Category	Date	Professional	Hours	Activity
18	7/14/2020	Greenblatt, Matthew	1.2	Conduct detailed review of the AlixPartners' Non-Cash Transfers report and continue work to develop initial testing procedures.
18	7/16/2020	Bromberg, Brian	0.5	Participate in discussion with forensic team to discuss cash transfer report.
18	7/16/2020	Costaldo, Nicole	1.0	Attend greater team call to debrief with Forensic Accounting team re: select transfers of value and Arms Length analysis.
18	7/16/2020	Greenblatt, Matthew	0.7	Continue review of AlixPartners' Non-Cash Transfers report and discuss with team to develop investigative workplan.
18	7/16/2020	Kyviakidis, Peter	0.5	Participate in discussion with restructuring team to discuss cash transfer report.
18	7/17/2020	Greenblatt, Matthew	1.4	Continue review of specific transactions and supporting documentation provided by AlixPartners related to the Non-Cash Transfers report.
18	7/20/2020	Bromberg, Brian	0.4	Participate in discussion with UCC re: cash transfers analysis.
18	7/20/2020	Greenblatt, Matthew	1.0	Participate with AlixPartners and FTI team and coordination of discussions with Province and Bates White regarding both the Cash Transfers report and the Non-Cash Transfers report.
18	7/21/2020	Costaldo, Nicole	0.5	Research Intralinks data room for the support for select transfers of interest and any associated agreements.
18	7/22/2020	Costaldo, Nicole	0.7	Participate in discussion with team regarding the agreements preliminarily identified in the Intralinks data room and what to review/details to extract from these agreements to further analyze the value of the associated transfers.
18	7/22/2020	Kyviakidis, Peter	0.8	Participate in discussion with team regarding the agreements preliminarily identified in the Intralinks data room and what to review/details to extract from these agreements to further analyze the value of the associated transfers.
18	7/23/2020	Greenblatt, Matthew	0.8	Participate in discussion with with Counsel, AlixPartners and FTI team to coordinate discussions with Province and Bates White regarding both the Cash Transfers report and the Non-Cash Transfers report.
18	7/24/2020	Costaldo, Nicole	0.4	Prepare inventory of agreements associated with selected transfers of value to be further analyzed on behalf of the Ad-Hoc Committee.
18	7/25/2020	Costaldo, Nicole	0.8	Continue to prepare inventory of agreements associated with selected transfers of value to be further analyzed on behalf of the Ad-Hoc Committee.
18	7/29/2020	Greenblatt, Matthew	0.5	Participate in discussion with Counsel, FTI team and UCC professionals regarding review of AlixPartners' workproduct.
18	7/29/2020	Mazzari, Meredith	0.8	Perform review and documentation of legal agreements governing select non-cash transfers.
18	7/30/2020	Mazzari, Meredith	3.0	Continue performing review and documentation of legal agreements governing select non-cash transfers.
18	7/31/2020	Mazzari, Meredith	2.8	Continue performing review and documentation of legal agreements governing select non-cash transfers.
18	7/31/2020	Mazzari, Meredith	1.2	Continue performing review and documentation of legal agreements governing select non-cash transfers.
18 Total			70.7	
19	7/1/2020	Simms, Steven	0.4	Review current engagement workstreams and coordinate with team on workplan.

EXHIBIT C
PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649
DETAIL OF TIME ENTRIES
FOR THE PERIOD JULY 1, 2020 TO JULY 31, 2020

Task Category	Date	Professional	Hours	Activity
19	7/6/2020	Kurtz, Emma	0.4	Update dataroom indexes to incorporate recently uploaded documents to share with team.
19	7/6/2020	Simms, Steven	0.4	Review current engagement workstreams and updates on diligence progress.
19	7/9/2020	Simms, Steven	0.3	Participate on update call on case status and process.
19	7/13/2020	Kurtz, Emma	0.6	Prepare updates to the dataroom index to include recently uploaded files to share with team.
19	7/13/2020	Simms, Steven	0.4	Review current engagement workstreams and updates on diligence progress.
19	7/16/2020	Kurtz, Emma	0.7	Review recently shared documents to the dataroom to update dataroom index.
19	7/17/2020	Simms, Steven	0.4	Review current engagement workstreams and coordindate with team on workplan.
19	7/21/2020	Simms, Steven	0.4	Participate on update call on case status and process.
19	7/27/2020	Kurtz, Emma	0.9	Review recently uploaded documents to the dataroom to update dataroom index and share with team.
19	7/28/2020	Simms, Steven	0.4	Review current engagement workstreams and updates on diligence progress.
19 Total			5.3	
21	7/8/2020	Kim, Ye Darm	1.5	Participate in call with committee re: distributable value discussions.
21	7/14/2020	Diaz, Matthew	0.2	Draft correspondence to the committee's professional re: updates on the distributable value/waterfall analysis.
21	7/15/2020	Kim, Ye Darm	1.5	Participate in weekly call with AHC re: diligence updates.
21	7/29/2020	Bromberg, Brian	1.4	Participate in weekly Committee call re: distributable value and public health initiatives.
21	7/29/2020	Diaz, Matthew	0.9	Prepare for the call with the AHC on recovery analysis and hearing updates.
21	7/29/2020	Diaz, Matthew	1.5	Participate in a call with the AHC to discuss the recovery analysis and the hearing update.
21	7/29/2020	Kim, Ye Darm	1.0	Participate in weekly call with AHC re: diligence updates.
21 Total			8.0	
22	6/30/2020	Bromberg, Brian	1.5	Participate in call re: bankruptcy strategy with public side entities.
22	7/1/2020	Diaz, Matthew	0.6	Review the financial update presentation for the tribal group.
22	7/1/2020	Diaz, Matthew	1.0	Participate on a call with the tribal group re: diligence updates.
22	7/1/2020	Diaz, Matthew	0.3	Participate in a call with Counsel to prepare for the call with the tribal group.
22	7/1/2020	Diaz, Matthew	0.5	Participate in a call with Houlihan to prepare for a call with the tribes.
22	7/1/2020	Kim, Ye Darm	1.0	Participate in meeting re: Tribal group diligence updates.
22	7/3/2020	Diaz, Matthew	0.7	Participate in calls with counsel to discuss the non consenting states presentation.
22	7/6/2020	Diaz, Matthew	1.2	Participate in a call with the non consenting states to discuss expected case proceeds.
22	7/6/2020	Diaz, Matthew	1.1	Prepare for the update call with the mediators.
22	7/6/2020	Diaz, Matthew	0.9	Participate in a call with Counsel to prepare for the calls with the NCSG and the mediators.
22	7/6/2020	Diaz, Matthew	1.8	Participate in a call with the mediators to discuss expected waterfall proceeds.
22	7/6/2020	Kim, Ye Darm	1.9	Participate in call re: financial update presentation to the mediators.
22	7/9/2020	Kim, Ye Darm	1.5	Participate in mediation financial presentation with claimant group.

EXHIBIT C
PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649
DETAIL OF TIME ENTRIES
FOR THE PERIOD JULY 1, 2020 TO JULY 31, 2020

Task Category	Date	Professional	Hours	Activity
22	7/9/2020	Diaz, Matthew	1.0	Participate in a call with the personal injury ad hoc group.
22	7/9/2020	Diaz, Matthew	0.5	Prepare for the call with the personal injury ad hoc group.
22	7/13/2020	Kim, Ye Darm	1.0	Participate in discussion with UCC advisors re: distributable value assumptions.
22	7/16/2020	Kim, Ye Darm	0.5	Participate in call with UCC advisors re: joint presentation on distributable value.
22	7/22/2020	Diaz, Matthew	2.0	Participate on call with the creditor body, mediators and the Debtors to discuss the presentation on estimated distributable value.
22	7/22/2020	Diaz, Matthew	1.5	Preparation for the call with the creditors and the mediators to discuss the joint creditor presentation on distributable value.
22	7/22/2020	Diaz, Matthew	1.7	Participate in meeting with the DOJ to discuss the PHI presentation.
22	7/22/2020	Kim, Ye Darm	1.2	Participate in call re: PHI initiatives with DOJ.
22 Total			23.4	
24	7/6/2020	Kim, Ye Darm	0.6	Process revisions to the May fee application.
24	7/8/2020	Kim, Ye Darm	3.6	Prepare draft of second interim fee application.
24	7/11/2020	Kim, Ye Darm	2.4	Process revisions to draft second interim fee application.
24	7/13/2020	Kim, Ye Darm	3.1	Process revisions to the second interim fee application.
24	7/13/2020	Kim, Ye Darm	1.2	Process revisions to the May fee application.
24	7/17/2020	Kim, Ye Darm	0.7	Prepare excel support for May fee application.
24	7/21/2020	Kim, Ye Darm	0.4	Prepare backup data for May fee application.
24	7/31/2020	Kim, Ye Darm	1.9	Review the June fee application.
24	7/31/2020	Kim, Ye Darm	2.6	Review the June fee application.
24	7/31/2020	Kim, Ye Darm	1.8	Prepare draft of June fee application.
24	7/31/2020	Kim, Ye Darm	2.8	Review the June fee application.
24 Total			21.1	
28	7/1/2020	Bromberg, Brian	2.4	Revise and prioritize inquiries for IAC accountants.
28	7/1/2020	Bromberg, Brian	0.4	Participate in call with counsel and Houlihan re: IAC reporting.
28	7/1/2020	Bromberg, Brian	0.2	Review proposed IAC diligence update summary.
28	7/1/2020	Bromberg, Brian	2.9	Review and edit updated question list for IAC accountant.
28	7/1/2020	Bromberg, Brian	0.6	Participate in call with Houlihan on IAC diligence.
28	7/1/2020	Bromberg, Brian	0.4	Review old list of diligence topics for call with Deutsche Bank.
28	7/1/2020	Bromberg, Brian	0.6	Discuss IAC sale process with Debtors' advisors.
28	7/1/2020	Diaz, Matthew	0.6	Draft email to the committee on the IAC due diligence.
28	7/1/2020	Diaz, Matthew	0.5	Participate in a call with KL and Houlihan to discuss IAC due diligence and next steps.
28	7/1/2020	Diaz, Matthew	1.1	Detail review of agenda and due diligence list for call with IAC accountant.
28	7/1/2020	Kim, Ye Darm	0.8	Review draft of diligence questions re: IAC accountant.
28	7/1/2020	Kim, Ye Darm	0.7	Participate in internal discussion re: IAC diligence meeting preparation.
28	7/2/2020	Bromberg, Brian	0.4	Summarize call notes from IAC Technical Operations diligence call.
28	7/2/2020	Bromberg, Brian	1.0	Participate in call with IAC Technical Operations head.
28	7/2/2020	Bromberg, Brian	0.7	Prepare for call with head of IAC Technical Operations.
28	7/2/2020	Bromberg, Brian	0.7	Revise and update Deutsche Bank diligence discussion topic list.
28	7/2/2020	Diaz, Matthew	0.5	Participate on a call with counsel and Houlihan to discuss the IAC due diligence.
28	7/2/2020	Diaz, Matthew	1.5	Review status of IAC due diligence and ongoing diligence calls.
28	7/2/2020	Kim, Ye Darm	0.7	Prepare updates for the IAC diligence summary update presentation.
28	7/2/2020	Kim, Ye Darm	1.0	Participate in diligence meeting re: IAC TechOps.

EXHIBIT C
PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649
DETAIL OF TIME ENTRIES
FOR THE PERIOD JULY 1, 2020 TO JULY 31, 2020

Task Category	Date	Professional	Hours	Activity
28	7/2/2020	Kim, Ye Darm	0.6	Review TechOps diligence question in preparation of meeting with Birgit Kudlek.
28	7/2/2020	Kim, Ye Darm	0.3	Process additional updates to IAC diligence update presentation.
28	7/3/2020	Bromberg, Brian	0.8	Revise new slides in IAC diligence update presentation.
28	7/3/2020	Bromberg, Brian	0.6	Participate in call on IAC diligence update presentations.
28	7/3/2020	Bromberg, Brian	2.2	Review IAC diligence update presentation and provide revisions.
28	7/3/2020	Kim, Ye Darm	0.6	Review revised questions list for IAC accountant re: IAC diligence.
28	7/3/2020	Kim, Ye Darm	1.2	Process revisions to IAC diligence update presentation.
28	7/3/2020	Kim, Ye Darm	0.9	Process updates to IAC diligence update presentation.
28	7/6/2020	Bromberg, Brian	0.5	Discuss IAC diligence updates with diligence subcommittee.
28	7/6/2020	Bromberg, Brian	1.1	Participate in diligence call with IAC LAM region head.
28	7/6/2020	Bromberg, Brian	0.6	Prepare for call with IAC LAM region head.
28	7/6/2020	Bromberg, Brian	0.4	Summarize notes from IAC LAM region head.
28	7/6/2020	Kim, Ye Darm	1.0	Participate in diligence meeting re: LAM diligence updates with region head.
28	7/6/2020	Kim, Ye Darm	1.0	Participate in meeting re: financial presentation on the IACs.
28	7/6/2020	Kurtz, Emma	0.9	Prepare updated outstanding diligence request lists to include follow up questions from recent diligence calls.
28	7/6/2020	Kurtz, Emma	1.0	Participate in diligence call with LAM region head to discuss LAM performance YTD and 2020 business plan.
28	7/7/2020	Bromberg, Brian	0.8	Compile diligence questions for discussion with IAC chief compliance officer.
28	7/7/2020	Kim, Ye Darm	1.0	Participate in diligence meeting re: IAC accountant diligence questions.
28	7/8/2020	Diaz, Matthew	0.4	Review of the due diligence list for the chief compliance officer diligence call.
28	7/8/2020	Kurtz, Emma	0.6	Prepare revisions to outstanding diligence request list re: completed requests and additional questions post call with Raman.
28	7/9/2020	Bromberg, Brian	0.8	Summarize call with IAC Chief Compliance Officer to discuss with team.
28	7/9/2020	Bromberg, Brian	0.5	Participate in call with Chief Compliance Officer of Mundipharma.
28	7/9/2020	Kim, Ye Darm	0.6	Review call notes re: compliance diligence call.
28	7/9/2020	Kim, Ye Darm	1.1	Review Celltrion Agreement Amendments from IACs.
28	7/9/2020	Kim, Ye Darm	0.6	Participate in meeting re: IAC compliance overview.
28	7/9/2020	Kurtz, Emma	0.4	Participate in call with head of compliance, Lori Reber, to compliance function.
28	7/10/2020	Kurtz, Emma	0.4	Prepare revisions to outstanding diligence request list to include additional questions and responses.
28	7/13/2020	Kim, Ye Darm	0.7	Review IAC business diligence materials for call.
28	7/14/2020	Bromberg, Brian	0.3	Prepare comment and revisions to business development call summary.
28	7/14/2020	Bromberg, Brian	0.4	Prepare for call with Deutsche Bank re: IAC sale process.
28	7/14/2020	Bromberg, Brian	1.0	Participate in call with Deutsche Bank re: IAC sale process.
28	7/14/2020	Bromberg, Brian	1.1	Participate in diligence call with IAC business development head.
28	7/14/2020	Bromberg, Brian	0.8	Review notes to prepare for call with IAC head of business development.
28	7/14/2020	Diaz, Matthew	1.2	Participate in a call with Deutsche Bank to discuss the IAC sale process.
28	7/14/2020	Kim, Ye Darm	1.2	Participate in call with Deutsche Bank re: IAC sale considerations.

EXHIBIT C
PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649
DETAIL OF TIME ENTRIES
FOR THE PERIOD JULY 1, 2020 TO JULY 31, 2020

Task Category	Date	Professional	Hours	Activity
28	7/14/2020	Kim, Ye Darm	0.6	Prepare and review materials for IAC business development diligence call.
28	7/14/2020	Kim, Ye Darm	0.9	Prepare summary of diligence call re: IAC business development.
28	7/14/2020	Kim, Ye Darm	0.8	Review information from Huron re: IAC R&D diligence responses.
28	7/14/2020	Kim, Ye Darm	0.8	Summarize call with Deutsche Bank re: IAC sale considerations.
28	7/14/2020	Kim, Ye Darm	1.0	Participate in call re: IAC business development diligence.
28	7/14/2020	Kurtz, Emma	1.2	Participate in call with Deutsche Bank to discuss IAC sale process.
28	7/14/2020	Kurtz, Emma	1.0	Participate in diligence call with Marco Cerato, head of business development, to discuss business plan overlay.
28	7/15/2020	Bromberg, Brian	1.0	Review updates to IAC cash flow information provided by Huron.
28	7/15/2020	Kurtz, Emma	1.4	Prepare analysis of Research and Development breakdown provided by Company to compare to the original business plan and the revised business plan.
28	7/17/2020	Bromberg, Brian	2.6	Review IAC diligence responses provided by Huron.
28	7/17/2020	Bromberg, Brian	1.4	Review R&D and capex breakdowns compared to original business plan.
28	7/17/2020	Kurtz, Emma	0.4	Review breakdown of Capital Expenditures provided by the Company and compare to the Cash Flow statement.
28	7/17/2020	Kurtz, Emma	1.1	Develop draft agenda and diligence questions in preparation for call with the Global Treasurer.
28	7/20/2020	Bromberg, Brian	2.6	Create consolidated diligence response for IACs.
28	7/20/2020	Bromberg, Brian	0.6	Prepare agenda for call with global treasurer.
28	7/20/2020	Bromberg, Brian	2.6	Prepare global follow up to provided IAC diligence responses.
28	7/20/2020	Bromberg, Brian	1.8	Review and answer Debtor questions on diligence update presentation.
28	7/20/2020	Kim, Ye Darm	0.9	Review summary of diligence responses from Huron re: IACs.
28	7/20/2020	Kurtz, Emma	0.8	Draft diligence responses to Huron re: recently received information and follow-up requests.
28	7/20/2020	Kurtz, Emma	1.7	Prepare comparison between diligence responses received from Huron and the previously received financial statements to evaluate responsiveness.
28	7/20/2020	Kurtz, Emma	0.4	Review responses to Steve Jamieson diligence requests to develop follow up questions.
28	7/20/2020	Kurtz, Emma	0.2	Prepare revisions to diligence response to Huron per internal comments.
28	7/21/2020	Bromberg, Brian	1.0	Finalize and send consolidated diligence response to IACs.
28	7/21/2020	Bromberg, Brian	0.7	Comment on non reliance letter re: IAC diligence.
28	7/22/2020	Kim, Ye Darm	0.7	Review Huron's running list of diligence questions re: IAC accountant.
28	7/22/2020	Kurtz, Emma	0.7	Prepare updates to outstanding diligence request list to incorporate responses from the Company and additional requests.
28	7/23/2020	Kim, Ye Darm	1.3	Review Huron diligence responses re: IAC accountant and prepare follow ups.
28	7/23/2020	Kurtz, Emma	1.2	Review additional responses received from the Company re: Steve Jamieson diligence questions.
28	7/24/2020	Bromberg, Brian	1.0	Participate in call with CEO of Mundipharma.
28	7/24/2020	Diaz, Matthew	1.0	Participate in a call with the CEO of Mundipharma to discuss his vision for the business.
28	7/24/2020	Diaz, Matthew	0.6	Prepare for the call with the CEO.

EXHIBIT C
PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649
DETAIL OF TIME ENTRIES
FOR THE PERIOD JULY 1, 2020 TO JULY 31, 2020

Task Category	Date	Professional	Hours	Activity
28	7/24/2020	Diaz, Matthew	1.5	Review the updated IAC diligence question list.
28	7/24/2020	Kim, Ye Darm	1.0	Participate in diligence call with IAC CEO.
28	7/24/2020	Kurtz, Emma	0.8	Participate in diligence call with Marc Princen, the global CEO of Mundipharma.
28	7/27/2020	Bromberg, Brian	0.7	Review topics for call with global treasurer.
28	7/27/2020	Bromberg, Brian	0.5	Coordinate outstanding IAC diligence requests with other case professionals.
28	7/27/2020	Bromberg, Brian	3.1	Review updated accountant files and question tracker for upcoming meeting.
28	7/27/2020	Bromberg, Brian	1.8	Review updated diligence questions list for IAC meeting with IAC treasurer.
28	7/27/2020	Kurtz, Emma	0.7	Analyze responses from company re: interest rate expense to evaluate variance from cash flow statement.
28	7/28/2020	Bromberg, Brian	0.6	Review call summary of diligence meeting with global treasurer.
28	7/28/2020	Bromberg, Brian	1.0	Participate in call with IAC global treasurer.
28	7/28/2020	Bromberg, Brian	0.5	Prepare for diligence call with IAC global treasurer.
28	7/28/2020	Kim, Ye Darm	1.0	Participate in diligence meeting with IAC treasurer.
28	7/28/2020	Kim, Ye Darm	0.9	Prepare summary of diligence call with IAC treasurer for internal distribution.
28	7/28/2020	Kurtz, Emma	1.0	Participate in diligence call with Daniel Jefferies, the newly hired global treasurer of Mundipharma.
28	7/29/2020	Diaz, Matthew	0.4	Review notes and related next steps from the call with the IAC treasurer.
28	7/30/2020	Bromberg, Brian	0.6	Participate in call with Debtor and UCC advisors on status of IAC diligence.
28	7/30/2020	Bromberg, Brian	1.8	Review provided financial diligence support documents from IACs.
28	7/30/2020	Bromberg, Brian	0.8	Prepare follow up diligence list and summary of items received.
28	7/30/2020	Bromberg, Brian	1.8	Participate in call with IAC accountant.
28	7/30/2020	Bromberg, Brian	0.5	Prepare for call with IAC accountant.
28	7/30/2020	Bromberg, Brian	0.6	Review and prepare revisions on call notes from IAC accountant meeting.
28	7/30/2020	Diaz, Matthew	0.5	Review call notes and related implications coming out of the call with IAC accountant.
28	7/30/2020	Kim, Ye Darm	0.7	Participate in discussion with UCC and Debtors' advisors re: IAC diligence workplan.
28	7/30/2020	Kim, Ye Darm	1.7	Participate in diligence call with Steve Jamieson re: IAC financials.
28	7/30/2020	Kurtz, Emma	0.8	Prepare detailed summary to share with team re: Steve Jamieson diligence call.
28	7/30/2020	Kurtz, Emma	1.7	Participate in diligence call with Steve Jamieson to discuss outstanding questions re: IAC financial statements.
28 Total			106.3	
GRAND TOTAL			596.0	